We provide the latest news
from the world of economics and finance
(RTTNews) - Shares of Regulus Therapeutics Inc. (RGLS) are soaring over 60 percent on Tuesday morning following the announcement of positive data from the company's Phase 1b MAD trial of of RGLS8429 along with private placement of $100 million.
The trial results showed that RGLS8429 was well-tolerated with no safety concerns in the patients with Autosomal Dominant Polycystic Kidney Disease or ADPKD.
Also, the investors had agreed to purchase the company's shares at $1.60 per share, and a new class of non-voting Class A-6 convertible preferred stock at $160.00 per share under the private placement.
Currently, Regulus's stock is trading at $2.22, up 60.14 percent over the previous close of $1.38 on the volume of around 82 million on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.